A real product, an unbuilt US market
Patrick Noel Daly is a Cork-born inventor who has spent the better part of two decades on one idea: a mattress surface sealed well enough that contamination stops at the surface instead of soaking into the foam core. He is the named inventor on the foundational patents behind the mechanism, a removable outer cover over a sealed multi-laminate envelope wrapped around a foam core that never touches fluid, and he built and licensed that technology, branded SimCair, into the Irish medical bedding channel through a licensed partner over more than seven years. Real revenue, a real channel, a product that works the way the patent says it works.
What did not exist was a US presence. No US brand, no US sales motion, no capital raised for the move, and a deck and financial model that had been built for an earlier stage of the company and had not kept pace with what a US raise and a US launch actually require. That is the gap NuWay Global came to Common Ground to close: a fractional commercial and capital-raise partnership to take the technology into the largest market for it, with Prince Capital running the licensed placement side of the raise.
Reading the evidence before repeating the pitch
The deck's clinical claims needed a real read, not a repeat. Patrick delivered two studies: a Cork Institute of Technology permeability assessment that challenged the SimCair envelope with MRSA, E. coli and C. difficile at a concentration far above realistic clinical contamination and recorded zero transmission across every replicate, and an Atrium Medical Centre Heerlen quality-improvement evaluation that tracked twenty-seven high-risk patients on the surface and recorded zero decubitus ulcers. Neither study is peer-reviewed, and we say so rather than dressing them up as something they are not. Both are institutionally credible, and the path to peer review is a defined four to six month, forty to eighty thousand dollar project rather than an open question.
Reading the studies in full also meant right-sizing the market claim built on top of them. The US pressure-relief mattress market is real, roughly two billion dollars today and growing toward three and a half billion by 2033, and the procurement lever underneath it is the more compelling story: hospitals in the bottom quartile of the federal hospital-acquired-condition ranking lose a percent of their entire Medicare reimbursement, often one to five million dollars a year, and pressure injuries are one of the highest-weighted categories in that ranking. Framed correctly to a hospital chief financial officer, SimCair is not a better mattress. It is protection against a seven figure annual penalty, and that reframing is what unlocks a procurement conversation rather than a clinical purchasing decision.
Why this one, and what we told ourselves to watch
Three things aligned before we said yes. The strategy the founder wanted, licensing SimCair and DreamCair into existing mattress and hospitality brands rather than building a direct-to-consumer brand from zero, is the strategy we would have recommended regardless. The regulatory pathway is a genuine bright spot: SimCair is Class I and 510(k)-exempt as a non-powered support surface, which is a sixty to ninety day path to the medical channel rather than a multi-year one. And the capital preference, family-office and philanthropic-capital investors, is the right kind of money for a company at this stage.
We also wrote down what we were not yet sure of, on the same page as the bull case rather than under it. The standard pre-raise diligence items, IP, trademark, licensee scope and the founder's record, are being closed as part of the engagement.
Where it stands now
As of September 2026, NuWay Global is in contract with Common Ground. The engagement is a commission agreement covering the business we bring to the United States, and the relationship moves from a prospect brief we built while deciding whether to take it on, to an active engagement doing the work: rebuilding the investor materials to the evidence that actually holds up, opening the commercial doors in medical, hospitality and licensing, and running the raise through Prince Capital's licensed desk.